Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acute myeloid leukemia with NPM1 somatic mutations is a subtype of acute myeloid leukemia with recurrent genetic abnormalities characterized by clonal proliferation of myeloid blasts harboring mutations of the NPM1 gene in the bone marrow, blood and other tissues. It is associated with multilineage dysplasia, involving the myeloid, monocytic, erythroid, and megakaryocytic cell lineages. Patients usually present with leukocytosis, thrombocytosis and nonspecific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain), with frequent extramedullary involvement typically presenting as gingival hyperplasia and lymphadenopathy.
Biomarker and diagnostic research for acute myeloid leukemia with NPM1 somatic mutations has been reported in the published literature.
No clinical trials have been registered for acute myeloid leukemia with NPM1 somatic mutations.
15 publications have been identified in PubMed for acute myeloid leukemia with NPM1 somatic mutations. Research spans Epidemiology / Natural History (40%), Basic Science / Preclinical (27%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 6 | 40% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 5:38 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute myeloid leukemia with NPM1 somatic mutations
Laboratory research |
4 |
27% |
Research summaries | 2 | 13% |
Testing and diagnosis research | 1 | 7% |
Clinical study results | 1 | 7% |
New treatment approaches | 1 | 7% |
Gao L (2026). [PMID: 41797886](https://pubmed.ncbi.nlm.nih.gov/41797886/). *Oncology letters*. [Basic Science / Preclinical]
Bazarbachi A (2026). [PMID: 41345260](https://pubmed.ncbi.nlm.nih.gov/41345260/). *Bone marrow transplantation*. [Epidemiology / Natural History]
Bartalucci N (2026). [PMID: 41792115](https://pubmed.ncbi.nlm.nih.gov/41792115/). *Blood cancer journal*. [Basic Science / Preclinical]
Mahmood R (2026). [PMID: 42123510](https://pubmed.ncbi.nlm.nih.gov/42123510/). *Int J Mol Sci*. [Basic Science / Preclinical]
Khudhair AM (2025). [PMID: 41312952](https://pubmed.ncbi.nlm.nih.gov/41312952/). *Asian Pacific journal of cancer prevention : APJCP*. [Epidemiology / Natural History]
Guo X (2025). [PMID: 40494174](https://pubmed.ncbi.nlm.nih.gov/40494174/). *Translational oncology*. [Epidemiology / Natural History]
Kotmayer L (2025). [PMID: 40568716](https://pubmed.ncbi.nlm.nih.gov/40568716/). *Haematologica*. [Review / Meta-Analysis]
Elfatih A (2025). [PMID: 41097716](https://pubmed.ncbi.nlm.nih.gov/41097716/). *Cancers*. [Review / Meta-Analysis]
Zhou W (2025). [PMID: 41136363](https://pubmed.ncbi.nlm.nih.gov/41136363/). *Blood cancer journal*. [Gene Therapy / Novel Therapeutics]
Mata DA (2024). [PMID: 38422618](https://pubmed.ncbi.nlm.nih.gov/38422618/). *Histopathology*. [Diagnostic / Biomarker]